Drug intelligence / Profile preview

ADGN-120

Development stage: Preclinical
Lead developer: DIVINCELL
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Peptides

Overview

ADGN-120 is a synthetic peptide therapeutic in preclinical development for the treatment of cancers driven by KRAS mutations. It acts as an inhibitor targeting multiple mutant forms of the KRAS protein, specifically KRAS G12C, G12D, and G12V. The drug is designed to modulate KRAS protein expression using peptide-based guide RNA (gRNA) technology. Initially developed by DIVINCELL SAS and also associated with Aanastra (formerly Aadigen), its primary indication is for neoplasms harboring relevant KRAS mutations[1][2][3].

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)KRASG12V (KRAS G12V)

Beyond the preview

Go deeper on ADGN-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADGN-120.